SEC Comment Letter 0000000000-24-000521 to IN8BIO, INC. (INAB) (CIK 0001740279) (INAB)
IN8BIO, INC. (INAB) (CIK 0001740279)
Date: Jan. 16, 2024 · CIK: 0001740279 · Accession: 0000000000-24-000521
AI Filing Summary & Sentiment
File numbers found in text: 333-276504
Letter
United States securities and exchange commission logo January 16, 2024 William Ho President and Chief Executive Officer IN8bio, Inc. 350 5th Avenue, Suite 5330 New York, New York 10118 Re:IN8bio, Inc. Registration Statement on Form S-3 Filed January 12, 2024 File No. 333-276504 Dear William Ho: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Joshua A. Kaufman, Esq.
Show Raw Text
United States securities and exchange commission logo
January 16, 2024
William Ho
President and Chief Executive Officer
IN8bio, Inc.
350 5th Avenue, Suite 5330
New York, New York 10118
Re:IN8bio, Inc.
Registration Statement on Form S-3
Filed January 12, 2024
File No. 333-276504
Dear William Ho:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Joshua A. Kaufman, Esq.